Optiver Holding’s Harvard Bioscience HBIO Stock Holding History

Optiver Holding’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$9	–	2494
2025 Q4	$9	Hold	1	–	–	﹤0.01%	2428
2025 Q3	$6	Buy	+1	New	+$5	﹤0.01%	2660

Other funds holding HBIO

WCM

Weber Capital Management San Francisco, California $100M AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CCM

Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return

MIM

Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optiver Holding's HBIO Position: Q1 2026 in Review

Optiver Holding sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 1 share — an estimated $9 sold.

Optiver Holding first reported a position in HBIO in Q3 2025 and held it in 2 quarters. The position peaked at $9 in Q4 2025. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

Optiver Holding reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
Optiver Holding sold 1 Harvard Bioscience share in Q1 2026, an estimated $9.
Optiver Holding first reported a position in Harvard Bioscience in Q3 2025 and held it in 2 quarters.
Optiver Holding's Harvard Bioscience position peaked at $9 in Q4 2025.
36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.